CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Wockhardt Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Wockhardt Ltd
Wockhardt Towers
Bandra Kurla Complex, Bandra (East)
Phone: +91 2226534444p:+91 2226534444 MUMBAI, 400051  India Ticker: WOCKPHARMAWOCKPHARMA
Business Summary
Wockhardt Limited is a pharmaceutical and biotechnology company. The Company's businesses include manufacture and marketing of pharmaceutical and bio-pharmaceutical formulations, active pharmaceutical ingredients (APIs) and vaccines. It manufactures a range of dosage forms, including sterile injectables and lyophilized products. The Company offers products in therapeutic areas of dermatology, cosmeceuticals, oncology, medical nutrition, osteoarthritis, pain management, nephrology, cough therapy and diabetology. The Company’s products across India includes Citawok, Citawok Forte, Citawok Plus, CONSEGNA 30/70 U-200 CART, CONSEGNA R U-200 CART, DARBOTIN PFS, DECDAN, DECDAN B, DECDAN B Injection, DECDAN LITE CREAM, Emrok, Emrok O, Erliso, FOSCHEK-S, Gabawok NT, GLARITUS CART, GLARITUS DISPO, Glimaday, INOGLA, Livatira, GLARITUS CART and VAL 450. It has manufacturing and research facilities in India, United States of America and the United Kingdom and a manufacturing facility in Ireland.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/20233/31/2023Yes---Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations
2836 Biological products, except diagnostic substances
3841 Surgical and medical instruments and apparatus
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Executive Chairman of the Board Habil FakhruddinKhorakiwala 78 3/31/2009 8/7/1999
Chief Financial Officer DeepakMadnani 6/7/2022
Compliance Officer, Company Secretary RashmiMamtura 8/19/2023 8/19/2023
6 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Morton Grove Pharmaceuticals, Inc. 6451 Main St Morton Grove IL United States
Wockhardt Bio AG Grafenauweg 6 ZUG ZUG Switzerland

Business Names
Business Name
5323
532300
Atlantis USA, Inc
41 additional Business Names available in full report.

General Information
Number of Employees: 2,740 (As of 3/31/2023)
Outstanding Shares: 153,400,936 (As of 3/26/2024)
Shareholders: 188,290
Stock Exchange: NSE
Fax Number: +91 2226523905


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Sunday, April 28, 2024